Vineet Laboratories Sets Rights Issue Price At Rs 30 Per Share

Vineet Laboratories Ltd, a Hyderabad-based pharmaceutical company, has finalized the pricing of its upcoming rights issue at Rs 30 per share. The board approved the issue to raise up to Rs 30 crore, reflecting the company’s intent to bolster its capital structure and fund expansion plans. A Rights Issue Committee has been formed to supervise the entire process, ensuring transparency and efficiency.  

Key highlights from the announcement include  

• The rights issue is priced at Rs 30 per share.  
• The company aims to raise up to Rs 30 crore through this offering.  
• Funds will be utilized to strengthen the capital base and support growth initiatives.  
• A Rights Issue Committee has been established to oversee the fundraising process.  
• The move is expected to enhance financial stability and provide resources for future expansion.  

This rights issue marks a significant step for Vineet Laboratories as it seeks to reinforce its financial foundation and pursue long-term growth opportunities in the pharmaceutical sector. The initiative reflects the company’s proactive approach to capital management and investor engagement.  

Sources: HDFC Sky, Vineet Laboratories Official Website, Economic Times